System: You are provided with a paragraph. Your goal is to automatically identify the most relevant tasks based on the content of the paragraph and generate an example of entailment (if the task conclusion can be logically inferred from the paragraph) and a different example of non-entailment (if it is unclear or the opposite conclusion is true). 

Step 1: Read the paragraph carefully. 
Step 2: Automatically decide which tasks are relevant based on the paragraph’s content. Relevant tasks may include, but are not limited to: 
    - Topic Classification 
    - Risk Classification
    - Sentiment Classification 
    - Tone Classification
    - Event Detection 
    - Entity Recognition 
    - Geographical Recognition 
    - Trend Detection 
    - Intent Detection 
    - Sector Identification 
    - Impact Classification 
    - Tense Identification (Past, Present, Future) 
    - Uncertainty Identification 

Step 3: For each relevant task you identify, generate two clear and concise examples whose labels match common practices for the task at hand: one for entailment and one for non-entailment. The example should speak about the text at the 3rd person. 
Step 4: Output the results in the following JSON format:

{
    'relevant_tasks': [
        {
            'task': <The automatically selected relevant task>,
            'examples': [
                {
                    'input': <The entailment example based on the paragraph>,
                    'label': 'entailment',
                },
                {
                    'input': <The non-entailment example (neutral or contradiction) based on the paragraph>,
                    'label': 'non-entailment',
                }
            ]
        },
        ...
    ]
}
User: In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because biopharmaceutical companies have experienced significant stock price volatility in recent years. Involvement in such litigation, could result in substantial costs and a diversion of management’s attention and resources, which could harm our business. On August 3, 2020, a stockholder of Selecta filed a stockholder derivative action, purportedly on behalf of Selecta and against certain current and former members of the Company’s Board of Directors, as well as one affiliated company owned by a current board member, in the Court of Chancery of the State of Delaware, namely Franchi v. Barabe, et al. The complaint alleges that the individual defendants breached their fiduciary duties and committed corporate waste when they authorized a private placement transaction, announced on December 19, 2019, at a price allegedly below fair value. The complaint further alleges that the four defendant directors who participated in the private placement were unjustly enriched in connection with the transaction. On September 25, 2020, the defendants filed a motion to dismiss the lawsuit. On November 6, 2020, the plaintiff filed an amended complaint, and the defendants filed a second motion to dismiss on January 8, 2021. On December 31, 2020, we received a litigation demand letter from two other putative stockholders relating to the same private placement transaction. On April 12, 2021, the Court of Chancery in the State of Delaware granted a motion to stay the litigation pending a review by a Special Committee appointed by the Company’s Board of Directors. While the litigation was stayed, the parties reached an agreement in principle to settle the matter, and on March 18, 2022, they submitted a Stipulation and Agreement of Settlement and other documentation to the Court for its approval of the settlement. On July 21, 2022, the Court held a settlement hearing, at which the settlement was approved. On August 1, 2022, the Court entered an Order and Final Judgment which dismissed the action, and all claims contained therein, with prejudice. We could receive other demands or be subject to other litigation. While we intend to vigorously defend against any demands which we believe to be without merit, there can be no assurance as to the outcome of any stockholder litigation. Unfavorable outcomes in securities class action litigation could require us to pay extensive damages, which could delay or prevent our ability to develop our product candidates and harm our operations.
Assistant: